- Uses heat and light energy to provide non-invasive and pain-free skin care
- InterceptCS™ provides cold sore prevention with controlled topical heat
- TherOZap™ relieves symptoms caused by insect and marine life bites and stings, holds potential for inhibiting mosquito-borne viruses
- A third product is in development to treat joint pain through the combination of cannabis and thermal technology
Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a progressive medical device technology company focused on serving the $21 billion cosmeceutical industry by providing products, devices and treatments that address dermatological needs. The company believes that clear and healthy skin should not be a privilege for those who can afford costly procedures and treatments, but rather a possibility that is accessible for all.
Heat and light energy are used by ThermaBright to provide non-invasive and pain-free skin care. This proprietary technology has received Class II medical device status from the U.S. Food and Drug Administration. Patent and trademark protection have also been initiated for products developed to incorporate medicinal cannabis into the use of the company’s thermal therapy tech.
InterceptCS is ThermaBright’s cold sore prevention device*. This device treats cold sores at their earliest appearance through the application of topical thermal technology with no risk of burning the skin. Used at the first sign of a cold sore, InterceptCS can prevent further symptoms from developing by killing cells that have been infected by the herpes simplex Type 1 virus.
The market potential for InterceptCS is high, with a reported 20-40 percent of the Canadian and United States population experiencing recurrent cold sore outbreaks. No prescription to use this device is required, making it more accessible to a larger market. Plans are in place to bring various models to market beyond the current single-use activator, further elevating the value for the customer.
Another of ThermaBright’s revolutionary products is TherOZap. This device uses thermal therapy as a second line of defense against insect bites. The device is used to relieve the pain, itch and swelling that can result from more than 20,000 types of insect and marine life bites and stings. These includes bees, wasps, hornets, mosquitos, black flies and jellyfish. Plans are in place to test the technology’s effectiveness in inhibiting mosquito-borne diseases such as the Zika and Dengue viruses.
A third product is in the works for a new pain relief device. This novel device is for the relief of back, knee or other joint pain. It combines the company’s thermal therapy tech with medical grade cannabis or cannabidiol (CBD) used as a cream or gel.
In preparation for this unique device, ThermaBright is in the process of creating a wholly owned subsidiary, according to a recent press release (http://ibn.fm/5ySjg). The company has indicated that an acquisition will be sought to further the development of this new product. The cannabis related device acquisitions, along with any products created, will be held in this new subsidiary.
For more information, visit the company’s website at www.ThermaBright.com
- Based on double blind placebo study the InterceptCS™ is approved for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” by Health Canada. The InterceptCS™ is not approved by the United States FDA for any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.